eligibility_summary
Inclusion: ECOG 0–1, ≥3‑mo life expectancy, advanced/metastatic solid tumor after/without effective standard therapy, RECIST v1.1 measurable/evaluable disease, adequate marrow/renal/hepatic function, archival/fresh tumor tissue, contraception. Exclusion: recent malignancy (≤3y), active CNS mets, major CV/respiratory disease, unresolved AEs, infections (HIV/HBV/HCV), prior topo‑I ADC or B7‑H3 therapy, recent anticancer/immunosuppressive/investigational tx, drug abuse, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06008366 (Phase 1/2). Intervention: 7MW3711, an intravenous antibody–drug conjugate (ADC) dosed Q3W. Mechanism/type: Monoclonal antibody targeting B7-H3 (CD276) linked to a cytotoxic topoisomerase I inhibitor payload, after binding B7-H3 on tumor cells, the ADC is internalized and releases the payload to inhibit topo I, causing DNA damage and tumor cell death. Study focus: Dose escalation/expansion to define MTD/RP2D, and assess safety, tolerability, PK, and preliminary efficacy in advanced solid tumors. Targets: B7-H3–expressing solid tumor cells, pathway affected is DNA replication/repair via topoisomerase I inhibition.